Gly-Low
Overeating
Hoskinson Health and Wellness ClinicEarly Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Overeating cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Guanfacine Maimonides Medical Center | Phase 4 | BB |
pf-08653944 Pfizer | Phase 2 | CCC |
pf-08653945 Pfizer | Phase 2 | CCC |
Betahistine Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1 | CC |
Metyrapone Eleonora Seelig | N/A | D |
Solu-Cortef Eleonora Seelig | N/A | D |
Same molecule, other indications
Gly-Low is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →